These antigens are typically categorized into two types: tumor-specific antigens, such as neoantigens arising from gene mutations, and tumor-associated antigens, such as CD19 and BCMA, which are predominantly overexpressed in tumor cells compared to normal cells 165. This evidence concerns the gene TNFRSF17 and neoplasm.